LSE:GSKPharmaceuticals
GSK Oncology Push And Siran Deal Shape Future Valuation Narrative
GSK (LSE:GSK) announced a global collaboration with Halozyme to use its subcutaneous drug delivery technology for antibody drug conjugates.
The company also agreed to acquire Siran Biotechnology, a China based RNA therapeutics company focused on siRNA therapies for cardiovascular and metabolic diseases.
Together, these moves expand GSK's oncology efforts and broaden its pipeline in cardiometabolic medicine.
For investors watching large pharmaceutical companies, GSK sits at the intersection...